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Haemophilus parasuis has emerged in the last years as one of the main causes 
of nursery mortality in modern swine husbandry, causing a severe systemic disease 
known as Glässer‟s disease. Control of this disease has traditionally been achieved by 
the use of commercial or autogenous bacterins, but these vaccines usually only prevent 
the disease caused by the homologous serovar, and more inconsistent results have been 
described when testing cross-protection. In addition, variable results have been achieved 
using some outer membrane proteins (Omps) in subunit vaccines.  
We have developed two vaccines based on nine native Omps with affinity to 
porcine transferrin (NPAPT) from H. parasuis, serovar 5, Nagasaki strain: one was 
adjuvanted with a mineral oil (Montanide IMS 2215 VG PR) and administered 
intramuscularly (NPAPT
IM
), whereas the other one was adjuvanted with a 
neuraminidase from Clostridium perfringens and administered intratracheally 
(NPAPT
IT
). Both vaccines were compared to two other subunit vaccines, consisting of 
recombinant transferrin-binding protein (rTbp) A or B fragments from Nagasaki strain, 
and to a commercial bacterin (Porcilis-Glässer
Ò
). Five groups of colostrum-deprived 
piglets were immunized with these vaccines, one group per each vaccine, and a group of 
nonvaccinated control piglets were challenged intratracheally with a lethal dose (3´10
8
 
CFU) of Nagasaki strain. The rTbpA and rTbpB vaccines showed a minimal protection, 
whereas two NPAPT and commercial vaccines protected strongly. Immunoproteomic 
studies was applied to the three better protected groups, and NPAPT
IT 
was that rendering 
the strongest immune response and against the highest number of proteins in the native 
Omp pool. Some of the proteins showing a scarce concentration in the pool (Omp2 or 
ABC transporter) yielded a high immune response but, contrarily to that expected, Tbps 
did not. In conclusion, these proteins could be effective candidates to prevent Glässer‟s 
disease by using subunit vaccines. 
 
